Name | LANTHANUM CARBONATE |
Synonyms | LANTHANUM CARBONATE LANTHANUM CARBONATE OCTAHYDRATE |
CAS | 6487-39-4 |
EINECS | 676-523-9 |
Molecular Formula | La2(CO3)3.XH2O |
Molar Mass | 457.85 |
Density | 2,6 g/cm3 |
Water Solubility | insoluble H2O; soluble dilute mineral acids [MER06] |
Appearance | Powder |
Specific Gravity | 2.6~2.7 |
Color | white |
Stability | Stable. |
Physical and Chemical Properties | Lanthanum carbonate has the chemical formula La2(CO3)3 · 8H2O. Molecular weight 601.97. White crystal. Relative density 2.6~2.7. Insoluble in water, acetone, soluble in dilute acid, slightly soluble in CO2 aqueous solution. Soluble in alkali metal carbonate, after dilution, it can crystallize out K[La(CO3)2]· 6H2O double salt. CO2 is released by heating. When heated, basic carbonate is first formed, and then burned to form oxide. Lanthanum and phosphorus carbonate has high binding power, and can play a good phosphorus-reducing effect in the whole digestive tract, with less adverse reactions, good cost performance and clinical compliance, so far it is an ideal phosphorus binder. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
usage and dosage | lanthanum carbonate is an oral medication. it must be swallowed after chewing. do not swallow the whole tablet. The tablets can be crushed to facilitate chewing. This product should be taken with food or immediately after a meal. The dose taken each time is the daily dose divided by the number of meals. Patients should follow the recommended diet to control phosphorus and fluid intake. This product is a chewable tablet, which can avoid excessive intake of liquid. When using this product, blood phosphorus should be monitored, and the dosage should be gradually adjusted every 2 to 3 weeks until the blood phosphorus reaches an acceptable level. After that, blood phosphorus should be monitored regularly. |
taboo | 1. allergic to lanthanum carbonate or any excipient in this product. 2. Hypophosphatemia. 3. Intestinal obstruction, intestinal obstruction and fecal impaction. |
indications | hyperphosphatemia. This product is a phosphorus binder for the treatment of hyperphosphatemia in patients with chronic renal failure on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) |